Scholarlink

<p>Atopic dermatitis (AD) is a chronic, relapsing, and heterogeneous skin disease characterized by eczematous morphology and intense pruritus, significantly impacting the quality of life of affected individuals. A primary cytokine implicated in AD is interleukin-13 (IL-13), which directly drives pruritus skin sensitization, contributing to pruritus. Lebrikizumab, a high-affinity IgG4 monoclonal antibody, targets IL-13 to block inflammatory and neuronal sensitization processes. This review aims to provide a comprehensive summary of lebrikizumab's efficacy in managing pruritus in patients with AD, focusing on data from the ADvocate 1&amp;2, ADjoin, ADmirable, and ADhere studies. Clinical trials have demonstrated rapid and sustained improvements in pruritus outcomes, with significant relief observed within days of treatment initiation and maintained over long periods. Lebrikizumab has shown efficacy across diverse populations, including adolescents, the elderly, and skin of color. By effectively targeting IL-13, lebrikizumab offers a valuable treatment option for moderate-to-severe AD, providing significant and sustained pruritus relief, skin clearance, and quality of life improvements.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Lebrikizumab on Pruritus: A Narrative Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Gil Yosipovitch,
  • Brian S. Kim,
  • Sonja Ständer,
  • Sarina B. Elmariah,
  • Vimal H. Prajapati,
  • Kenji Kabashima,
  • Gaia Gallo,
  • Maria Jose Rueda,
  • Evangeline Pierce,
  • Yuxin Ding,
  • Shawn G. Kwatra

摘要

Atopic dermatitis (AD) is a chronic, relapsing, and heterogeneous skin disease characterized by eczematous morphology and intense pruritus, significantly impacting the quality of life of affected individuals. A primary cytokine implicated in AD is interleukin-13 (IL-13), which directly drives pruritus skin sensitization, contributing to pruritus. Lebrikizumab, a high-affinity IgG4 monoclonal antibody, targets IL-13 to block inflammatory and neuronal sensitization processes. This review aims to provide a comprehensive summary of lebrikizumab's efficacy in managing pruritus in patients with AD, focusing on data from the ADvocate 1&2, ADjoin, ADmirable, and ADhere studies. Clinical trials have demonstrated rapid and sustained improvements in pruritus outcomes, with significant relief observed within days of treatment initiation and maintained over long periods. Lebrikizumab has shown efficacy across diverse populations, including adolescents, the elderly, and skin of color. By effectively targeting IL-13, lebrikizumab offers a valuable treatment option for moderate-to-severe AD, providing significant and sustained pruritus relief, skin clearance, and quality of life improvements.